|

[18F]-PI-2620 Clinical Trials

3 actively recruiting trials across 3 locations

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • University of Pennsylvania1
  • Michael J. Fox Foundation for Parkinson's Research1
  • Life Molecular Imaging Ltd1

Indications

  • Alzheimer's Disease2
  • Alzheimer Disease2
  • Cognitively Normal1
  • Frontotemporal Lobar Degeneration1
  • Parkinson's Disease1

Phoenix, Arizona1 trial

[18F]PI-2620 Phase 3 Histopathological Study

Barrow Neurological Institute

Phase 3

New Haven, Connecticut1 trial

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

Institute for Neurodegenerative Disorders / XingImaging, LLC

Phase 2

Philadelphia, Pennsylvania1 trial

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

Perelman Center for Advance Medicine

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.